Firstly, to assess the efficacy of baricitinib at additional timepoints on mitigating the loss of plasma C-peptide; secondly, to assess the effect of baricitinib on secondary clinical outcomes including insulin dose, haemoglobin A1c (HbA1c) and estimated C-peptide (CPEST) [29], a surrogate measure of beta cell function; and finally, to assess the safety and tolerability of baricitinib in participants with T1D. This evidence concerns the gene INS and type 1 diabetes mellitus.